Hodges Capital Management Inc. Buys 664 Shares of Eli Lilly and Company $LLY

Hodges Capital Management Inc. grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 6.5% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 10,835 shares of the company’s stock after buying an additional 664 shares during the period. Hodges Capital Management Inc.’s holdings in Eli Lilly and Company were worth $8,446,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $27,000. Blume Capital Management Inc. raised its stake in shares of Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after purchasing an additional 14 shares in the last quarter. IMG Wealth Management Inc. bought a new position in Eli Lilly and Company in the second quarter worth $35,000. TD Capital Management LLC lifted its position in Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after purchasing an additional 31 shares during the period. Finally, Family CFO Inc acquired a new stake in Eli Lilly and Company during the second quarter worth $54,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 1.5%

NYSE LLY opened at $923.35 on Monday. The stock’s 50 day simple moving average is $799.97 and its 200 day simple moving average is $775.01. Eli Lilly and Company has a one year low of $623.78 and a one year high of $955.46. The firm has a market cap of $872.92 billion, a PE ratio of 60.35, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s revenue was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Insider Activity at Eli Lilly and Company

In related news, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO David A. Ricks purchased 1,632 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 4,314 shares of company stock worth $2,766,929 in the last quarter. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on LLY. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, November 3rd. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. JPMorgan Chase & Co. decreased their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, September 16th. Finally, Daiwa America lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $983.76.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.